Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

This study was an open label, three period, fixed sequence study in healthy male and female subjects performed at a single study center. The study comprised: * Screening during Days -28 to -2 (both inclusive). * Three treatment periods separated by a washout period of at least 10 days. Duration of Treatment: The duration of participation for each subject was approximately 2 months and 2 weeks (including the screening period).